Walleye Capital
DWTX

Walleye Capital’s Dogwood Therapeutics DWTX Stock Holding History

Walleye Capital’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,573
Closed -$38.8K – 4449
2022
Q4 		$38.8K Buy
6,573
+573
+10% +$4.32K ﹤0.01% 2577
2022
Q3 		$57K Buy
+6,000
New +$845K ﹤0.01% 2560

Other funds holding DWTX

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Walleye Capital's DWTX Position: Q1 2023 in Review

Walleye Capital sold out of Dogwood Therapeutics (DWTX) in Q1 2023, closing a stake of 6,573 shares — an estimated $38.8K sold.

Walleye Capital first reported a position in DWTX in Q3 2022 and held it in 2 quarters. The position peaked at $57K in Q3 2022. 23 funds tracked by Wall St. Rank hold DWTX as of Q1 2023.

  • Walleye Capital reported no remaining Dogwood Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Walleye Capital sold 6,573 Dogwood Therapeutics shares in Q1 2023, an estimated $38.8K.
  • Walleye Capital first reported a position in Dogwood Therapeutics in Q3 2022 and held it in 2 quarters.
  • Walleye Capital's Dogwood Therapeutics position peaked at $57K in Q3 2022.
  • 23 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.